An official website of the United States government
Publication Information
Affiliation
Department of Biostatistics, University of Kansas Medical Center, Mail Stop 1026, 3901 Rainbow Blvd., Kansas City, KS, 66160, USA. kmckenzie5@kumc.edu.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.; Section of Nephrology, University of Chicago School of Medicine, Chicago, IL, USA.; Division of Nephrology, University of Alabama and the Department of Veterans Affairs Medical Center, Birmingham, AL, USA.; Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA.; Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Legacy Good Samaritan Hospital, Portland, OR, USA.; Division of Nephrology and Hypertension and the Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City, KS, USA.; Department of Biostatistics, University of Kansas Medical Center, Mail Stop 1026, 3901 Rainbow Blvd., Kansas City, KS, 66160, USA.
Authors
McKenzie Katelyn A, El Ters Mirelle, Torres Vicente E, Harris Peter C, Chapman Arlene B, Mrug Michal, Rahbari-Oskoui Frederic F, Bae Kyongtae Ty, Landsittel Douglas P, Bennett William M, Yu Alan S L, Mahnken Jonathan D
Studies
Abstract
Caffeine has been proposed, based on in vitro cultured cell studies, to accelerate progression of autosomal dominant polycystic kidney disease (ADPKD) by increasing kidney size. Since ADPKD patients are advised to minimize caffeine intake, we investigated the effect of caffeine on disease progression in the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP), a prospective, observational cohort study.